Register Login
Register to leave comments
  • News bot Oct. 1, 2025, 8:21 p.m.

    📋 Terns Pharmaceuticals, Inc. (TERN) - Financial Results

    Filing Date: 2022-05-16

    Accepted: 2022-05-16 16:24:36

    Event Type: Financial Results

    Event Details:

    Terns Pharmaceuticals Inc (TERN) Reports Q2 2022 Financial Results Terns Pharmaceuticals Inc (TERN) announced its financial results for the period ending Q2 2022. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 151268
      • 501: Thyroid hormone receptor
      • β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR
      • β compared to other THR
        • expected in the second half of 2023
        • expected in 2023
        • expected in second half of 2023

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Operating Expenses Loss From Operations 13.82K 13.30K $529.00 +3.98%
    Operating Expenses Interest Income 69.00 11.00 $58.00 +527.27%
    Operating Expenses Total Other Income Expense 4.00 13.00 $-9.00 -69.23%
    Operating Expenses Net Loss 13.77K 13.34K $436.00 +3.27%
    Cash Equivalents Marketable Securities 151.27K 165.98K $-14.71K -8.86%
    Loss from Operations 13.82K 13.30K $529.00 +3.98%
    Interest Income 69.00 11.00 $58.00 +527.27%
    Net Loss 13.77K 13.34K $436.00 +3.27%
    Cash and Marketable Securities 151.27K 165.98K $-14.71K -8.86%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Terns Pharmaceuticals Inc
    • CIK: 0001831363
    • Ticker Symbol: TERN
    • Period End Date: 2022-05-16
    • Document Type: 8-K

Search

News categories